A drug first designed to prevent cancer cells from multiplying has a second effect: it switches immune cells that turn down the body’s attack on tumors back into the kind that amplify it. This is the finding of a study led by researchers from NYU Langone Medical Center and published recently in Cancer Immunology Research.
According to experiments in mice, macrophages – immune cells that home in on tumors – take in the drug nab-paclitaxel (brand name Abraxane). Once inside these cells, say the study authors, the drug changes them so that they signal for an aggressive anti-tumor immune response. Read more . . .